N/A N=4,832 An Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of COPD
Chronic Obstructive Pulmonary Disease
Primary: Healthcare Utilization — 1080; 920 Participants — p=0.041
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,600 Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Infections, Rotavirus · Rotavirus Vaccines
Primary: Anti-Rota Virus (Anti-RV) Immunoglobulin A (IgA) Antibody Concentrations in the Human Rotavirus (HRV) Liquid Formulation Groups (Liq_A, Liq_B and Liq_C) — 155.7; 147.3…
N/A N=23 Dietary Nitrate and Physiological Aging
Aging
Primary: Change in Carotid Chemosensitivity Following 4 Weeks of Dietary Nitrate Supplementation and Placebo in Older Adults — -0.13; -0.05; -0.10; -0.11 L/min/%SpO2
Phase 4 N=4 Neuroimaging the Expectancy Versus Pharmacotherapy Effect of Adderall on Cognitive Performance
Expectancy Versus Pharmacotherapy Effect of Adderall
Primary: Number of Participants Consistently Attending and Completing Four Neuroimaging Sessions — 4; 4; 4; 4 Participants
Phase 1 N=32 A Study of Single or Repeated Doses of Glucagon in Participants With Diabetes
Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to T(AUC[0-tlast]) of Baseline-Adjusted Glucagon — 2470; 4100; 4640; 3610…
N/A N=91 PRIORITI-MTF Study- Testing Patient Response to the IDEO
Leg Injuries · Trauma
Primary: Four Square Step Test — 8.0 seconds
Phase 3 N=871 Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis
Bacterial Vaginosis
Primary: Clinical Cure — 135; 129; 74 Participants — p=<0.001
Phase 2 N=21 Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
Small Cell Lung Cancer · Extensive-stage Small Cell Lung Cancer
Primary: Phase I: Confirmation of Recommended Phase II Dose — 3; 1 mg/kg dose
N/A N=14 Electrical Stimulation in Diabetic Peripheral Neuropathy
NMES · Control
Primary: Nerve Conduction Speed (Common Peroneal Nerve) — 33.93; 44.1; 41.63; 44.13 m/sec
N/A N=5 Early Feasibility Study to Evaluate the Efficacy of the RenewalNail™ Plasma Treatment System in Patients With Onychomycosis (Fungal Nail)
Onychomycosis of Toenail · Onychomycosis
Primary: Mycological Cure — 2 Participants
N/A N=40 Venous Insufficiency and Neuromuscular Stimulation
Chronic Venous Disease · Venous Insufficiency · Deep Venous Obstruction
Primary: Percentage Change of Haemodynamic Flow — 34.8; 62.8; 9; 14.8 % change
Phase 2 N=108 Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Colorectal Cancer
Primary: PFS Probability Rate at 9 Months in the Dose Escalation Arm — 45; 48; 0; 55 percent probability
Phase 2 N=45 ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD
Prediabetic State · Non-alcoholic Fatty Liver Disease · Type 2 Diabetes Mellitus
Primary: Change From Baseline in Matsuda Index — 1.22; 1.04; -0.02; 0.24 unit on a scale — p=0.2483
N/A N=162 Retrospective CI532 Hearing Performance
Hearing Loss
Primary: Change From Pre-operative (Daily Listening Condition) Baseline Speech Understanding in Quiet at 6 Months Post-operative (Best Aided Conditions). — 26.1 Percent correct
Phase 3 N=458 A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)
Depressive Disorder, Major
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at the End of Trial — -5; -4.7 Score on a Scale — p=0.6482